COSENTYX Solution for Injection
Secukinumab
150 mg/ml
AesculapiusFarmaceutici S.r.l
| Pack size | 1 Pre-filled pen (1 ml) |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 2114.55 AED |
Indications
COSENTYX Solution for Injection is used for:
Indicated for, moderate-to-severe plaque psoriasis, in patients who are candidates for systemic therapy or phototherapy, indication includes, treatment for moderate-to-severe scalp psoriasis, active psoriatic arthritis, active ankylosing spondylitis
Adult Dose
Subcutaneous
Plaque psoriasis
Adult: 300 mg every week for 5 doses, followed by 300 mg every month. Each 300 mg dose is given as 2 injections of 150 mg. Review treatment if no response within 16 weeks of initial dose.
Psoriatic arthritis
Adult: 150 mg every week for 5 doses, followed by 150 mg every month, may increase to 300 mg if response is inadequate. Coexistent moderate to severe plaque psoriasis or anti-TNF? inadequate responders: 300 mg every week for 5 doses, followed by 300 mg every month. Review treatment if there is no response after 16 weeks.
Ankylosing spondylitis
Adult: 150 mg once weekly for 5 weeks, then once monthly thereafter. Review treatment if there is no response after 16 weeks.
Child Dose
Renal Dose
Administration
Powd for inj: Reconstitute 150 mg vial w/ 1 mL sterile water for inj to make a 150 mg/mL soln.
Contra Indications
Serious infections (e.g. active TB, hepatitis B, sepsis). Admin of live vaccines.
Precautions
Patient w/ history of recurrent or chronic infection, inflammatory bowel disease (e.g. Crohn’s disease). Pregnancy and lactation.
Pregnancy-Lactation
Pregnancy Category: B
Lactation: Unknown if distributed in human breast milk
Interactions
May enhance the adverse effects and diminish the therapeutic effect of live vaccines.
Adverse Effects
Side effects of Secukinumab :
>10%
Infections (28.7%)
Nasopharyngitis (11.4-12.3%)
1-10%
Diarrhea (2.6-4.1%)
URT infection (2.5-3.2%)
Rhinitis (1.4%)
Oral herpes (0.1-1.3%)
Pharyngitis (1-1.2%)
Urticaria (0.6-1.2%)
Rhinorrhea (0.3-1.2%)
Mechanism of Action
Secukinumab is a recombinant fully human IgG1/K monoclonal antibody that selectively binds to interleukin-17A (IL-17A), a cytokine involved in normal inflammatory and immune responses, thus inhibiting the release of proinflammatory cytokines, chemokines, and mediators of tissue damage.
Note
COSENTYX 150 mg/ml Solution for Injection manufactured by AesculapiusFarmaceutici S.r.l. Its generic name is Secukinumab. COSENTYX is availble in Saudi Arabia.
Farmaco SA drug index information on COSENTYX Solution for Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.